A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CARCINOMAS
Sponsor: |
Pfizer |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ8228 |
U.S. Govt. ID: |
NCT02315066 |
Contact: |
Naiyer Rizvi, MD: 212-305-3997 / nar2144@cumc.columbia.edu |
The purpose of this research is to learn about the effects of 2 new investigational drugs, PF-04518600 and PF-05082566. PF-04518600 and PF-05082566 are antibodies (a type of protein) which have been shown to stimulate the immune system. Research has shown that an immune response like this can work against tumor cells to slow tumor growth by causing tumor cells to die. PF-04518600 alone and in combination with PF-05082566 are being investigated as possible treatments for research subjects/participants with advanced liver cancer, skin cancer (melanoma), kidney cancer, head and neck cancer, stomach cancer, cervical cancer, gastric cancer, bladder cancer or lung cancer.
This study is closed
Have you been diagnosed with advanced liver, skin, kidney, head/neck, stomach, cervical, gastric, bladder or lung cancer? |
Yes |
No |